Pharma Tech
Nov 13, 2026, 7:53 PM

AHA26: Boehringer’s survodutide establishes CV safety in SYNCHRONIZE-CVOT
KOLs interviewed by GlobalData were more optimistic about survodutide’s potential in fatty liver disease (MASLD) than weight loss.
Read more




